

Date of Submission: 4<sup>th</sup> August 2020

|   |   |
|---|---|
| To,<br>The Secretary<br>Listing Department<br>BSE Limited<br>Department of Corporate Services<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001<br><b>Scrip Code - 539551</b> | To,<br>The Secretary<br>Listing Department<br>National Stock Exchange of India Limited<br>Exchange Plaza, Bandra Kurla Complex<br>Mumbai – 400 050<br><b>Stock Code- NH</b> |
|---|---|

Dear Sir/Madam,

**Sub:**

1. **Outcome of Board meeting held on 4<sup>th</sup> August 2020 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and**
2. **Financial Results for the First quarter ended 30<sup>th</sup> June 2020 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to the subject, we wish to inform you that:

1. The meeting of Board of Directors commenced at **2:00 PM** and ended at **6:00 PM**.
2. The Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30<sup>th</sup> June 2020 together with Limited Review Report has been reviewed by Audit Committee and approved by the Board of Directors.

Publication of results in Newspapers is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

Yours faithfully,

**For NARAYANA HRUDAYALAYA LIMITED**

*Sridhar S*  
Sridhar S

Group Company Secretary, Legal and Compliance Officer

# Deloitte Haskins & Sells LLP

Chartered Accountants  
Prestige Trade Tower, Level 19  
45, Palace Road, High Grounds  
Bengaluru - 560 001  
Karnataka, India


Tel: +91 80 6188 6000  
Fax: +91 80 6188 6011

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **NARAYANA HRUDAYALAYA LIMITED** ("the Company"), for the quarter ended June 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. **Emphasis of Matter**  
  
We draw attention to Note 5 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the Company.

Our conclusion on the Statement is not modified in respect of the above matter.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Monisha Parikh**  
Partner  
(Membership No. 47840)  
UDIN: 20047840AAAACO6607

Place: Bengaluru  
Date: August 04, 2020

Regd. Office: Indus Towers Limited, Tower 3, 2nd Floor, Sitapura Industrial Area, Sector 18, Gurgaon - 122 001, Haryana, India.  
LLP Registration No. AAB-6737



**Narayana Hrudayalaya Limited**

Registered office : No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India  
Corporate office : 2nd Floor, No. 261/A, Bommasandra Industrial Area, Hosur Road, Bengaluru 560099, Karnataka, India  
CIN : L85110KA2000PLC027497, Website : www.narayanahealth.org, Email: investorrelations@nhhospitals.org

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020**

| Sl. No. | Particulars   | (₹ in Million, except per share data) |                          |                          |                        |
|---------|---|---------------------------------------|--------------------------|--------------------------|------------------------|
|         |   | Quarter ended                         |                          | Year ended               |                        |
|         |   | 30-Jun-20<br>(Unaudited)              | 31-Mar-20<br>(Unaudited) | 30-Jun-19<br>(Unaudited) | 31-Mar-20<br>(Audited) |
| 1.      | <b>Income</b>   |                                       |                          |                          |                        |
|         | (a) Revenue from operations   | 2,375.08                              | 5,250.19                 | 5,583.94                 | 22,393.51              |
|         | (b) Other income (refer note 4)   | 496.73                                | 74.34                    | 67.09                    | 241.42                 |
|         | <b>Total income</b>   | <b>2,871.81</b>                       | <b>5,324.53</b>          | <b>5,651.03</b>          | <b>22,634.93</b>       |
| 2.      | <b>Expenses</b>   |                                       |                          |                          |                        |
|         | (a) Purchases of medical consumables, drugs and surgical instruments  | 696.01                                | 1,126.70                 | 1,441.47                 | 5,403.30               |
|         | (b) Changes in inventories of medical consumables, drugs and surgical instruments -(Increase) / Decrease          | 36.16                                 | 207.09                   | (29.97)                  | 155.08                 |
|         | (c) Employee benefits expense   | 991.15                                | 1,111.67                 | 1,074.05                 | 4,486.19               |
|         | (d) Professional fees to doctors  | 822.78                                | 1,212.42                 | 1,253.51                 | 5,060.41               |
|         | (e) Other expenses  | 784.33                                | 1,157.95                 | 1,156.37                 | 4,721.62               |
|         | <b>Expenses before depreciation and amortisation, finance costs and exceptional items</b>                         | <b>3,330.43</b>                       | <b>4,815.83</b>          | <b>4,895.43</b>          | <b>19,826.60</b>       |
| 3.      | <b>Earnings / (loss) before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)</b> | <b>(458.62)</b>                       | <b>508.70</b>            | <b>755.60</b>            | <b>2,808.33</b>        |
| 4.      | Finance costs   | 111.81                                | 109.05                   | 134.17                   | 491.13                 |
| 5.      | Depreciation and amortisation expense   | 312.45                                | 326.85                   | 297.53                   | 1,277.16               |
| 6.      | <b>Total expenses (2+4+5)</b>   | <b>3,754.69</b>                       | <b>5,251.73</b>          | <b>5,327.13</b>          | <b>21,594.89</b>       |
| 7.      | <b>Profit / (loss) before tax and exceptional items (1-6)</b>   | <b>(882.88)</b>                       | <b>72.80</b>             | <b>323.90</b>            | <b>1,040.04</b>        |
| 8.      | Exceptional items   | -                                     | -                        | -                        | -                      |
| 9.      | <b>Profit / (loss) before tax (7-8)</b>   | <b>(882.88)</b>                       | <b>72.80</b>             | <b>323.90</b>            | <b>1,040.04</b>        |
| 10.     | <b>Tax expense</b>  |                                       |                          |                          |                        |
|         | (a) Current tax   |                                       |                          |                          |                        |
|         | -Current year   | -                                     | 36.52                    | 133.84                   | 388.52                 |
|         | -Prior year   | -                                     | (15.00)                  | -                        | (15.00)                |
|         | (b) Deferred tax charge/(credit)  | (310.84)                              | (0.57)                   | (15.79)                  | (10.91)                |
|         | (c) Mat credit entitlement  | -                                     | -                        | -                        | -                      |
|         | <b>Total tax expense</b>  | <b>(310.84)</b>                       | <b>20.95</b>             | <b>118.05</b>            | <b>362.61</b>          |
| 11.     | <b>Profit / (loss) for the period/ year (9-10)</b>  | <b>(572.04)</b>                       | <b>51.85</b>             | <b>205.85</b>            | <b>677.43</b>          |
| 12.     | <b>Other comprehensive income</b>   |                                       |                          |                          |                        |
|         | <i>Items that will not be reclassified subsequently to profit or loss</i>   |                                       |                          |                          |                        |
|         | (i) Re-measurement gains/(losses) on defined benefit plans  | (0.91)                                | (1.58)                   | (1.21)                   | (3.06)                 |
|         | (ii) Income tax effect  | 0.32                                  | 0.55                     | 0.42                     | 1.07                   |
|         | <i>Items that will be reclassified subsequently to profit or loss</i>   |                                       |                          |                          |                        |
|         | (i) Effective portion of gains/ (losses) in cash flow hedge   | (3.21)                                | (45.89)                  | (24.25)                  | (67.64)                |
|         | (ii) Income tax effect  | 1.12                                  | 16.03                    | 8.47                     | 23.63                  |
|         | <b>Other comprehensive income, net of taxes</b>   | <b>(2.68)</b>                         | <b>(30.89)</b>           | <b>(16.57)</b>           | <b>(46.00)</b>         |
| 13.     | <b>Total comprehensive income / (loss) (11+12)</b>  | <b>(574.72)</b>                       | <b>20.96</b>             | <b>189.28</b>            | <b>631.43</b>          |
| 14.     | Paid-up equity share capital<br>(Face value of ₹ 10 each)   | 2,043.61                              | 2,043.61                 | 2,043.61                 | 2,043.61               |
| 15.     | Reserves (Other Equity)   | -                                     | -                        | -                        | 9,615.17               |
| 16.     | Earnings / (loss) per share<br>(of ₹ 10 each) :   | not annualised                        | not annualised           | not annualised           | annualised             |
|         | (a) Basic   | (2.82)                                | 0.26                     | 1.02                     | 3.34                   |
|         | (b) Diluted   | (2.82)                                | 0.26                     | 1.01                     | 3.34                   |
|         | See accompanying notes to the financial results   |                                       |                          |                          |                        |



*Handwritten signature/initials*

**Notes:**

1. The Statement of unaudited standalone financial results ('the Statement') of Narayana Hrudayalaya Limited ('the Company') for the quarter ended June 30, 2020 has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors on August 4, 2020. The Statement has been subjected to a limited review by Deloitte Haskins & Sells LLP, the statutory auditor of the Company.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.
4. Other Income for the quarter ended June 30, 2020 includes dividend income from Narayana Cayman Holdings Limited, a wholly owned subsidiary amounting to Rs.455.22 Million.
5. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Company during the quarter ended June 30, 2020. As at June 30, 2020, the Management has used internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic. The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.



for and on behalf of the Board of Directors of  
Narayana Hrudayalaya Limited

**Dr. Emmanuel Rupert**  
Managing Director & Group CEO

Place: Bengaluru  
Date: August 4, 2020



**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS  
TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **NARAYANA HRUDAYALAYA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss of its associates for the quarter ended June 30, 2020 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

| Sl. No. | Entity  | Relationship        |
|---------|---|---------------------|
| 1.      | Narayana Hrudayalaya Limited (NHL)                                  | Parent              |
| 2.      | Narayana Institute for Advanced Research Private Limited (NIARPL)   | Subsidiary          |
| 3.      | Narayana Hospitals Private Limited (NHPL)                           | Subsidiary          |
| 4.      | Narayana Health Institutions Private Limited (NHIPL)                | Subsidiary          |
| 5.      | Meridian Medical Research & Hospital Limited (MMRHL)                | Subsidiary          |
| 6.      | Narayana Vaishno Devi Specialty Hospitals Private Limited (NVDSHPL) | Subsidiary          |
| 7.      | Narayana Hrudayalaya Surgical Hospital Private Limited (NHSPL)      | Subsidiary          |
| 8.      | Narayana Cayman Holdings Limited (NCHL)                             | Subsidiary          |
| 9.      | Narayana Health North America LLC                                   | Subsidiary          |
| 10.     | Narayana Holdings Private Limited (NHDPL)                           | Subsidiary of NCHL  |
| 11.     | Health City Cayman Islands Limited (HCCI)                           | Subsidiary of NCHL  |
| 12.     | NH Health Bangladesh Private Limited (NHHBPL)                       | Subsidiary of NHDPL |
| 13.     | ISO Healthcare Group  | Associate of NHDPL  |
| 14.     | CURA Technologies Inc.  | Associate of NCHL   |

Regd. Office: Indiabulls Finance Centre, Tower 3, 2<sup>nd</sup> - 32<sup>nd</sup> Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400 013, Maharashtra, India.  
(LLP Identification No. AAB-8737)

# Deloitte Haskins & Sells LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matter


We draw attention to Note 5 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

7. We did not review the interim financial information of three subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. Nil for the quarter, total net loss after tax of Rs. 4.94 Million for the quarter ended June 30, 2020 and total comprehensive loss of Rs. 4.93 Million for the quarter ended June 30, 2020, as considered in the Statement. The consolidated unaudited financial results also include the Group's share of loss after tax of Rs.10.21 Million as considered in the Statement, in respect of two associates, whose interim financial information have not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

**For DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Monisha Parikh**  
Partner  
(Membership No. 47840)  
UDIN : 20047840AAAACP9115

Place: Bengaluru  
Date: August 04, 2020



**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020**

| Sl. No. | Particulars   | (₹ in Million, except per share data) |                 |                 |                  |
|---------|---|---------------------------------------|-----------------|-----------------|------------------|
|         |   | Quarter ended                         |                 | Year ended      |                  |
|         |   | 30-Jun-20                             | 31-Mar-20       | 30-Jun-19       | 31-Mar-20        |
|         |   | (Unaudited)                           | (Unaudited)     | (Unaudited)     | (Audited)        |
| 1.      | <b>Income</b>   |                                       |                 |                 |                  |
|         | (a) Revenue from operations   | 3,935.00                              | 7,429.48        | 7,773.66        | 31,278.09        |
|         | (b) Other income  | 46.52                                 | 70.37           | 48.32           | 237.64           |
|         | <b>Total income</b>   | <b>3,981.52</b>                       | <b>7,499.85</b> | <b>7,821.98</b> | <b>31,515.73</b> |
| 2.      | <b>Expenses</b>   |                                       |                 |                 |                  |
|         | (a) Purchases of medical consumables, drugs and surgical instruments  | 1,042.65                              | 1,599.76        | 1,877.31        | 7,223.64         |
|         | (b) Changes in inventories of medical consumables, drugs and surgical instruments -(Increase) / Decrease          | 62.74                                 | 187.85          | 25.87           | 229.50           |
|         | (c) Employee benefits expense   | 1,529.06                              | 1,679.87        | 1,631.83        | 6,736.97         |
|         | (d) Professional fees to doctors  | 1,031.45                              | 1,520.15        | 1,550.79        | 6,289.79         |
|         | (e) Other expenses  | 1,178.88                              | 1,484.40        | 1,659.84        | 6,569.09         |
|         | <b>Expenses before depreciation and amortisation, finance costs and exceptional items</b>                         | <b>4,844.78</b>                       | <b>6,472.03</b> | <b>6,745.64</b> | <b>27,048.99</b> |
| 3.      | <b>Earnings / (Loss) before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITDA)</b> | <b>(863.26)</b>                       | <b>1,027.82</b> | <b>1,076.34</b> | <b>4,466.74</b>  |
| 4.      | Finance costs   | 197.47                                | 207.82          | 222.03          | 852.73           |
| 5.      | Depreciation and amortisation expense   | 463.51                                | 550.86          | 414.21          | 1,857.96         |
| 6.      | <b>Total Expenses (2+4+5)</b>   | <b>5,505.76</b>                       | <b>7,230.71</b> | <b>7,381.88</b> | <b>29,759.68</b> |
| 7.      | <b>Profit / (Loss) before tax and exceptional items (1-6)</b>   | <b>(1,524.24)</b>                     | <b>269.14</b>   | <b>440.10</b>   | <b>1,756.05</b>  |
| 8.      | Exceptional items (refer note 4)  | -                                     | (108.70)        | -               | (108.70)         |
| 9.      | <b>Profit / (Loss) before share of loss of equity accounted investees and income tax (7+8)</b>                    | <b>(1,524.24)</b>                     | <b>160.44</b>   | <b>440.10</b>   | <b>1,647.35</b>  |
| 10.     | Share of (loss) / profit of equity accounted investees  | (10.21)                               | (4.50)          | (7.28)          | (34.30)          |
| 11.     | <b>Profit / (Loss) before tax (9+10)</b>  | <b>(1,534.45)</b>                     | <b>155.94</b>   | <b>432.82</b>   | <b>1,613.05</b>  |
| 12.     | <b>Tax expense</b>  |                                       |                 |                 |                  |
|         | (a) Current tax   |                                       |                 |                 |                  |
|         | -Current year   | -                                     | 41.96           | 143.35          | 425.38           |
|         | -Prior year   | -                                     | (15.00)         | -               | (15.00)          |
|         | (b) Deferred tax charge/(credit)  | (336.83)                              | 14.20           | (3.85)          | 48.72            |
|         | (c) MAT credit entitlement  | -                                     | (5.15)          | (9.51)          | (36.57)          |
|         | <b>Total Tax expenses</b>   | <b>(336.83)</b>                       | <b>36.01</b>    | <b>129.99</b>   | <b>422.53</b>    |
| 13.     | <b>Profit / (Loss) for the period/ year (11-12)</b>   | <b>(1,197.62)</b>                     | <b>119.93</b>   | <b>302.83</b>   | <b>1,190.52</b>  |
| 14.     | <b>Other Comprehensive Income</b>   |                                       |                 |                 |                  |
|         | <i>Items that will not be reclassified subsequently to profit or loss</i>   |                                       |                 |                 |                  |
|         | (i) Re-measurement gains/(losses) on defined benefit plans  | 1.66                                  | (2.97)          | (0.91)          | (8.67)           |
|         | (ii) Income tax effect  | (0.24)                                | 0.73            | 0.34            | 1.62             |
|         | <i>Items that will be reclassified subsequently to profit or loss</i>   |                                       |                 |                 |                  |
|         | (i) Effective portion of gains/ (losses) in cash flow hedges  | (1.87)                                | (112.14)        | (59.43)         | (161.69)         |
|         | (ii) Income tax effect  | 1.12                                  | 16.03           | 8.47            | 23.63            |
|         | (iii) Effective portion of gains/ (losses) of net investment hedge in a foreign operation                         | (2.73)                                | (85.08)         | 5.09            | (131.22)         |
|         | (iv) Exchange differences in translating the financial statement of foreign operations                            | 0.37                                  | 220.30          | (12.68)         | 322.91           |
|         | <b>Other Comprehensive Income, net of taxes</b>   | <b>(1.69)</b>                         | <b>36.87</b>    | <b>(59.12)</b>  | <b>46.58</b>     |
| 15.     | <b>Total comprehensive income / (loss) (13+14)</b>  | <b>(1,199.31)</b>                     | <b>156.80</b>   | <b>243.71</b>   | <b>1,237.10</b>  |
| 16.     | <b>Profit / (Loss) attributable to:</b>   |                                       |                 |                 |                  |
|         | Owners of the company   | (1,197.05)                            | 119.59          | 302.51          | 1,189.16         |
|         | Non-controlling interests   | (0.57)                                | 0.34            | 0.32            | 1.36             |
|         | <b>Profit / (Loss) for the period/ year</b>   | <b>(1,197.62)</b>                     | <b>119.93</b>   | <b>302.83</b>   | <b>1,190.52</b>  |
| 17.     | <b>Other comprehensive income attributable to:</b>  |                                       |                 |                 |                  |
|         | Owners of the company   | (1.70)                                | 36.88           | (59.12)         | 46.60            |
|         | Non-controlling interests   | 0.01                                  | (0.01)          | -               | (0.02)           |
|         | <b>Other comprehensive income for the period/ year</b>  | <b>(1.69)</b>                         | <b>36.87</b>    | <b>(59.12)</b>  | <b>46.58</b>     |
| 18.     | <b>Total comprehensive income / (loss) attributable to:</b>   |                                       |                 |                 |                  |
|         | Owners of the company   | (1,198.75)                            | 156.47          | 243.39          | 1,235.76         |
|         | Non-controlling interests   | (0.56)                                | 0.33            | 0.32            | 1.34             |
|         | <b>Total comprehensive income / (loss) for the period/ year (16+17)</b>   | <b>(1,199.31)</b>                     | <b>156.80</b>   | <b>243.71</b>   | <b>1,237.10</b>  |
| 19.     | Paid-up equity share capital<br>(Face value of ₹ 10 each)   | 2,043.61                              | 2,043.61        | 2,043.61        | 2,043.61         |
| 20.     | Reserves (Other Equity)   | -                                     | -               | -               | 9,316.03         |
| 21.     | Earnings / (loss) per share<br>(of ₹ 10 each)   | not annualised                        | not annualised  | not annualised  | annualised       |
|         | (a) Basic   | (5.90)                                | 0.59            | 1.49            | 5.86             |
|         | (b) Diluted   | (5.90)                                | 0.59            | 1.49            | 5.86             |
|         | See accompanying notes to the financial results   |                                       |                 |                 |                  |



Notes :

- 1 The Statement of unaudited consolidated financial results ('the Statement') of Narayana Hrudayalaya Limited (the 'Parent' / 'Company') and its subsidiaries (together referred to as the 'Group') and its share of the loss in associates for the quarter ended June 30, 2020 has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors on August 4, 2020. The Statement has been subjected to a limited review by Deloitte Haskins & Sells LLP, the statutory auditor or the Company.
- 2 The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms or the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 The Group's operating segment is 'Medical and Healthcare Services'. Since the Group has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.
- 4 The Group had carried out an impairment assessment of one of the Cash Generating Units i.e. Dharamshila Narayana Super Speciality Hospital (hereinafter referred to as "the CGU") in one of its subsidiaries Narayana Hrudayalaya Surgical Hospital Private Limited due to the continued losses incurred in the CGU and more importantly the relatively weaker forecasts due to COVID-19. Based on the detailed impairment evaluation carried out by the Group duly considering the future cash flows of the CGU, the Group had recorded an impairment of ₹ 108.70 Million during the quarter and year ended March 31, 2020 and had disclosed the same as an exceptional item in the Statement of Profit and Loss.
- 5 On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Group during the quarter ended June 30, 2020. As at June 30, 2020, the Management has used internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic. The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Group will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

Place: Bengaluru  
Date: August 4, 2020



for and on behalf of the Board of Directors of  
**Narayana Hrudayalaya Limited**

**Dr. Emmanuel Rupert**  
Managing Director & Group CEO